BALCHEM (BCPC)

Balchem Corporation reported strong financial performance for Q3 2025, continuing its double-digit sales and earnings growth. The company also demonstrated strong cash flows supporting a healthy balance sheet, with all three business segments delivering solid growth. Growth is further strengthened by "better for you" food and nutrition market trends, benefiting Balchem's portfolio of specialty nutrients and functional solutions. Additionally, Balchem has surpassed its 2030 GHG emissions reduction goal, reducing Scope 1 and 2 emissions by 32%.

• Balchem reported record quarterly consolidated sales of $268 million, an 11.5% increase year-over-year, marking its 25th consecutive quarter of year-over-year adjusted EBITDA growth.
• The company achieved record quarterly adjusted EBITDA of $71 million, up 11%, and record adjusted diluted EPS of $1.35, an increase of 19.5% compared to the prior year.
• Human Nutrition and Health segment sales grew 14.3% to $174 million, and the Specialty Products segment grew 7.5%, with Plant Nutrition growing 13%.
• Balchem is investing in a new microencapsulation plant with twice the capacity, expected to be completed and producing by early 2027, to support the 26% growth in its encapsulates business.
• The company's net debt decreased to $89 million, resulting in a leverage ratio of 0.3, and maintains a positive outlook for the remainder of the year.

• Balchem reported record Q3 2025 consolidated revenue of $268 million, an 11.5% increase year-over-year, marking the 25th consecutive quarter of year-over-year adjusted EBITDA growth.
• The company achieved record adjusted EBITDA of $71 million (up 11% year-over-year) and record adjusted diluted EPS of $1.35 (up 19.5% year-over-year).
• All three segments contributed to growth, with the Human Nutrition and Health segment's sales increasing 14.3% to $174 million.
• Construction of a new microencapsulation manufacturing facility in Orange County is expected to be completed in early 2027 and operational by mid-2027, doubling capacity for this high-growth product line.
• The European Union's preliminary anti-dumping duties on China-origin choline chloride are anticipated to receive final approval by the end of 2025, with a five-year term.

• Balchem Corporation reported record net sales of $267.6 million for the third quarter of 2025, an 11.5% increase compared to the prior year quarter.
• The company achieved GAAP net earnings of $40.3 million, up 19.1%, and record adjusted EBITDA of $71.4 million, up 11.0% from the prior year quarter.
• GAAP earnings per share were $1.24 and adjusted earnings per share were $1.35 for Q3 2025, compared to $1.03 and $1.13 respectively in the prior year quarter.
• All three reporting segments, Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products, experienced sales and earnings growth. Balchem is also moving forward with a new microencapsulation manufacturing facility in Orange County, NY, which will more than double capacity , and made net repayments of $36.0 million on its revolving debt, bringing net debt to $88.9 million with a 0.3 times leverage ratio.

• Balchem Corporation reported record net sales of $267.6 million for the third quarter ended September 30, 2025, an 11.5% increase compared to the prior year quarter.
• GAAP net earnings for Q3 2025 were $40.3 million, a 19.1% increase from the prior year, with GAAP earnings per share of $1.24 and record adjusted earnings per share of $1.35.
• The company achieved record adjusted EBITDA of $71.4 million, up 11.0% from the prior year quarter, and generated free cash flow of $50.7 million.
• All three reporting segments experienced sales and earnings from operations growth.
• Balchem received approvals to proceed with a new state-of-the-art food ingredient and nutraceutical microencapsulation manufacturing facility in Orange County, NY, which will more than double capacity.

• Balchem Corp reported record Q2 2025 consolidated sales of $255 million, an increase of 9.1% year-over-year, and record adjusted diluted EPS of $1.27.
• The company plans to build a new $36 million microencapsulation manufacturing facility in New York, which is expected to more than double its capacity and support continued double-digit growth.
• Management maintains a positive outlook for the second half of 2025, citing healthy demand across most end markets.
• Provisional anti-dumping duties of 95% to 120% on Chinese choline by the European Commission are anticipated to positively impact the Animal Nutrition and Health segment.